Effectiveness of combined intermittent preventive treatment for children and timely home treatment for malaria control

Collins K Ahorlu, Kwadwo A Koram, Atsu K Seakey, Mitchell G Weiss, Collins K Ahorlu, Kwadwo A Koram, Atsu K Seakey, Mitchell G Weiss

Abstract

Background: Whiles awaiting for the arrival of an effective and affordable malaria vaccine, there is a need to make use of the available control tools to reduce malaria risk, especially in children under five years and pregnant women. Intermittent preventive treatment (IPT) has recently been accepted as an important component of the malaria control strategy. This study explored the potential of a strategy of intermittent preventive treatment for children (IPTC) and timely treatment of malaria-related febrile illness in the home in reducing the parasite prevalence and malaria morbidity in young children in a coastal village in Ghana.

Methods: The study combined home-based delivery of IPTC among six to 60 months old and home treatment of suspected febrile malaria illness within 24 hours. All children between six and 60 months of age received intermittent preventive treatment using amodiaquine and artesunate, delivered by community assistants every four months (three times in 12 months). Malaria parasite prevalence surveys were conducted before the first and after the third dose of IPTC.

Results: Parasite prevalence was reduced from 25% to 3% (p < 0.00, Mann-Whitney) one year after the inception of the two interventions. At baseline, 13.8% of the children were febrile (axillary temperature greater than or equal to 37.5 degree Celsius) compared to 2.2% at evaluation (post IPTC3 combined with timely home management of fever) (p < 0.00, Mann-Whitney).

Conclusion: The evaluation result indicates that IPTC given three times in a year combined with timely treatment of febrile malaria illness, impacts significantly on the parasite prevalence. The marked reduction in the parasite prevalence with this strategy points to the potential for reducing malaria-related childhood morbidity and mortality, and this should be explored by control programme managers.

References

    1. World Health Organization. The Africa Malaria Report. WHO, Geneva; 2003. (WHO/CDS/MAL/2003.1093)
    1. Adjuik M, Smith T, Clark S, Todd J, Garrib A, Kinfu Y, Kahn K, Mola M, Ashraf A, Masanja H, Adazu K, Sacarlal J, Alam N, Marra A, Gbangou A, Mwageni E, Binka F. Cause-specific mortality rates in sub-Saharan Africa and Bangladesh. Bull World Health Organ. 2006;84:181–188. doi: 10.2471/BLT.05.026492.
    1. Ghana Health Service. Final Draft Antimalarial Drug Policy for Ghana, Accra. 2004.
    1. Koram KA, Quaye L, Abuaku B. Comparative efficacy of anti malarial drugs including ACTs in the treatment of uncomplicated malaria in young children under 5 in Ghana. Acta Trop. 2005;95:194–203. doi: 10.1016/j.actatropica.2005.06.018.
    1. Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95:194–203. doi: 10.1016/j.actatropica.2005.06.018.
    1. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer H. Plasmodium falciparum: susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian school children. Trans R Soc Trop Med Hyg. 1994;88:440–442. doi: 10.1016/0035-9203(94)90424-3.
    1. Ahorlu CK, Koram KA, Ahorlu C, de Savigny D, Weiss M. Sociocultural determinants of treatment delay for childhood malaria in southern Ghana. Trop Med Int Health. 2006;11:1022–1031. doi: 10.1111/j.1365-3156.2006.01660.x.
    1. Ahorlu CK, Koram KA, Ahorlu C, de Savigny D, Weiss M. Community concepts of malaria-related illness with and without convulsions in southern Ghana. Malar J. 2005;4:47. doi: 10.1186/1475-2875-4-47.
    1. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, Toure OB, Sacko M, Doumbo OK. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J. 2008;7:123. doi: 10.1186/1475-2875-7-123.
    1. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccination in Tanzania infants: a randomised, placebo-controlled, double-blind trial. Lancet. 2001;357:1471–1477. doi: 10.1016/S0140-6736(00)04643-2.
    1. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, Theander TG, Bygbjerg. Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in infants in Tanzania: a randomised placebo-control trial. Lancet. 2003;361:1853–1860. doi: 10.1016/S0140-6736(03)13504-0.
    1. Cissé B, Sokhna C, Boulanger D, Milet J, Bâel H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet. 2006;367:659–67. doi: 10.1016/S0140-6736(06)68264-0.
    1. Kish, Leslie. Survey Sampling. John Wiley & Sons, NY; 1965.
    1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727–733. doi: 10.1136/bmj.331.7519.727.
    1. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I. Is the expanded programme on immunization the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa. Trop Med Int Health. 2007;12:743–50.
    1. Zikusooka CM, McIntyre D, Barnes KI. Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar J. 2008;7:176. doi: 10.1186/1475-2875-7-176.
    1. Goodman CA, Mills AJ. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Plan. 1999;14:301–312. doi: 10.1093/heapol/14.4.301.

Source: PubMed

3
S'abonner